Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin
Disease progression · participants with unresectable hepatocellular carcinoma
It is very uncertain whether recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) changes proportion of people with disease progression compared with hydroxycamptothecin (very low certainty).
1 finding from 1 review
- RR 2.4 [0.57, 10.08]1 study · 48 participantsVery low